Lee Schwartzberg, MD
Enriched profileChief, Medical Oncology and Hematology, Renown Institute for Cancer (William N. Pennington Cancer Institute) · Renown Institute for Cancer
Lee Schwartzberg is Chief, Medical Oncology and Hematology, Renown Institute for Cancer (William N. Pennington Cancer Institute) at Renown Institute for Cancer. OpenAlex indexes 686 publications with 20,363 citations (h-index 63); ClinicalTrials.gov lists 17 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Lee Schwartzberg, MD, is Chief, Medical Oncology and Hematology, Renown Institute for Cancer (William N. Pennington Cancer Institute). The public record shows 686 publications with 20,363 citations (h-index 63), centered on Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 55 companies.
- Most recent indexed publication: 2026 · Journal of the National Cancer Institute
- Top research focus: Cancer Treatment and Pharmacology
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 55 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 250.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Sponsor: Exai Bio Inc.
- Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Sponsor: Novartis Pharmaceuticals
Industry payments
Updated 27 Aug 2026
55 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202535 payments$50,531openpaymentsdata.cms.gov ↗
- Cornerstone Specialty Network LLCProgram year20252 payments$36,990openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year202526 payments$22,823openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
71.7%Aromatase Inhibitor47.5%Anastrozole77%Letrozole23%Part D≥76 patientsEstrogen Agonist/Antagonist18%Tamoxifen Citrate100%Part D≥33 patientsNervous system
5.6%Phenothiazine3.9%Prochlorperazine Maleate100%Part D≥21 patientsGabapentinoids1.7%Gabapentin100%Part D<11 patientsSensory organs
5.2%Corticosteroid5.2%Dexamethasone100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
238 congress contributions (2004–2025) across AACR, ASCO, ASH, ESMO, SABCS per OpenAlex. The most recent:
- Healthcare provider experiences in managing antibody-drug conjugate dosing adjustments due to nausea and vomiting: SABCS and ESMO survey findings.
ASCO Annual Meeting
ASCO2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.
Journal of the National Cancer Institute
Article2026 - Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence.
Clinical cancer research
Article2025 - Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy.
JCO clinical cancer informatics
Clinical Trial2024 - 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Supportive care in cancer
Review2023
Most-cited works
by citation count (OpenAlex)- 01
- 02Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyArticle1,617 citations2018
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
exai.bio/about/leadership/lee-schwartzberg
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →exai.bio ↗ - Other
renown.org/about/newsroom/dr-lee-schwartzberg-honored-with-2023-legends-in-cancer-award
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →renown.org ↗ - Other
renown.org/find-a-doctor/1306878228-lee-schwartzberg-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →renown.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York Medical College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →exai.bio ↗ - Fellowship
Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →accc-cancer.org ↗ - M.S.
Biochemistry, Buffalo State University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →exai.bio ↗
Editorial & leadership roles
journal and society appointments- Former Board of Directors Member
National Comprehensive Cancer Network (NCCN)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Guideline Panel Member (seven-year tenure)
NCCN Breast, Antiemesis, and Myeloid Growth Factor Panels
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Founding Editor-in-Chief
Community Oncology (journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →accc-cancer.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →renown.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →accc-cancer.org ↗
- Fellow
American College of Physicians (FACP)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →accc-cancer.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Clinical Medicine
University of Nevada, Reno School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →exai.bio ↗ - Chief Medical Officer
Exai Bio
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →exai.bio ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practiceupdate.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles